Clinical Trial Update: Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating apixaban for prevention of venous thromboembolism in patients with multiple myeloma treated with IMiDs has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Venous Thromboembolism

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Myeloma, Venous Thromboembolism | Phase 3 | Status: COMPLETED